Keen Chung, Ph.D., currently serves as Associate Director of Gene Therapy at Repligen Corporation, overseeing the Gene Therapy upstream team and analytics team while managing the development and optimization of TFDF-based perfusion processes for AAV and LVV production. With prior experience at Pall Corporation as Analytics Team Manager and Principal Scientist, Keen has led analytical teams and contributed to cell culture manufacturing of various viral vectors. Keen's background encompasses significant postdoctoral research at SRI International and UT Southwestern Medical Center, focusing on integrin b6 in cancer, alongside early research as a Graduate Assistant at Penn State University. Keen holds a Ph.D. in Molecular Toxicology from Penn State University and has additional postdoctoral training in Internal Medicine-Hematology.
This person is not in any teams
This person is not in any offices